Loading stock data…
ZTS
$114.16-0.81 (-0.70%)
Market ClosedLast close May 1
Zoetis Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Zoetis Inc. in the Healthcare sector is trading at $114.16. The stock is currently near its 52-week low of $112.97, remaining 12.9% below its 200-day moving average. Technical signals show neutral RSI of 38 and bearish MACD signal, explaining why ZTS maintains its current current market pressure. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 38) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$114.16
Potential Upside
74.7%
Whystock Fair Value$199.45
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus17 analysts
Buy
Mean target$148.88+30.4%
Range$127.00 – $190.00
Fundamentals
Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health solutions for the animal health industry in the Uni...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$48.99B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
19.28
Beta
Defensive asset. Lower volatility than the S&P 500.
0.97
Div Yield
Strong income play. Yield provides a meaningful total return floor.
183.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
78.41%
Volume
Today's trading volume
2.54M
Recent News
A Look At Zoetis (ZTS) Valuation As Earnings Optimism And AI Diagnostics News Draw Fresh Focus
Why Zoetis Stock Is Back in Focus Zoetis (ZTS) is drawing fresh attention as investors weigh upbeat expectations for its upcoming first quarter 2026 earnings, recent product news around its Vetscan OptiCell platform, and supportive analyst commentary. See our latest analysis for Zoetis. Despite upbeat expectations around the May 7 earnings release and fresh attention on its AI-powered diagnostics, Zoetis’ recent share price performance has been weak. The 30 day share price return shows a...
Zoetis Gears Up to Report Q1 Earnings: Is a Beat in the Cards?
ZTS eyes a Q1 beat as companion animal products and international growth offset U.S. weakness ahead of its May 7 earnings report.
Zoetis Inc. (ZTS) Announces Expansion of Capabilities of Vetscan OptiCell
Zoetis Inc. (NYSE:ZTS) is one of the best drug stocks to buy according to analysts. On April 21, Zoetis Inc. (NYSE:ZTS) announced that it is expanding the capabilities of Vetscan OptiCell, which is its cartridge-based, artificial intelligence-powered hematology analyzer. The expansion marks the next step in the platform’s evolution, with the company stating that the update […]
Zoetis (ZTS) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Zoetis (ZTS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.